The use of patient-derived xenograft (PDX) models has been on the rise for the last several years. As preclinical work aims to be more relevant to clinical settings and more predictive of clinical outcomes, there are times when the use of PDX models is determined to be necessary to optimize translatability.

At MI Bioresearch, we have utilized PDX models in the brain, breast, lung, and pancreas and applied MRI, PET, CT, and fluorescence imaging, as appropriate, to validate tumor growth in the orthotopic setting and to assess select standard of care agents in vivo.

Collaborating with various PDX providers, we leverage our expertise in conventional pharmacology that underlies our in vivo imaging and focal beam radiation capabilities to PDX model studies. Our goal is to provide you the most clinically relevant and predictive set of cancer drug discovery tools available to date.